Zanvastro is the first approved treatment for Alexander disease

The disease strikes fewer than 1 in a million people. Until September 3, none of them had an approved drug, only supportive care while the disorder dismantled motor function, swallowing, and breathing. That day the FDA approved Zanvastro (zilganersen), the first treatment in the history of Alexander disease.

Alexander disease was first described in 1949. The reason it took 77 years to reach a drug is structural: too few patients to fund classic development, a disease spectrum that runs from infancy into the fifties, and a protein that accumulates inside the brain's support cells rather than on the surface of a tumor. Companies do not usually spend a decade on a disease that affects a few hundred people worldwide.

The approval arrived two and a half weeks ahead of its September 22 Prescription Drug User Fee Act (PDUFA) deadline, the FDA's own review date. Along the way the agency had granted the drug orphan, fast track, breakthrough therapy, and rare pediatric disease designations. With the decision the agency also handed it a Rare Pediatric Disease Priority Review Voucher (PRV), a program reward that can speed a later application through review.

For patients with Alexander disease and their families, there have been no approved treatment options, only supportive care while the disease progresses. Today's approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease.— Emily Freilich, M.D., Director, Division of Neurology I, FDA Center for Drug Evaluation and Research

A disease medicine skipped for decades

Alexander disease runs off a single mutation class. Faulty variants in the GFAP gene, short for glial fibrillary acidic protein, cause that protein to overproduce and pile up inside astrocytes, the cells that support neurons and maintain the myelin sheath around nerve fibers. The buildup damages the nervous system slowly. Motor function fades, coordination goes, swallowing and airway protection fail. Death usually follows within 14 to 25 years of the first symptoms.

Prevalence sits at roughly 1 in 1 to 3 million people. Onset can come in infancy or as late as the fifties, which makes the disease unusually hard to study: a pediatric trial and an adult trial are different projects, and both are tiny.

The therapy that finally broke the deadlock is an antisense oligonucleotide, a short strand of nucleic acid that binds GFAP messenger RNA and degrades it, cutting off the abnormal protein before it accumulates. Zanvastro is given as an intrathecal injection into the spinal canal every three months by a trained professional, and the FDA cleared it for patients from infancy through adulthood.

What 54 patients can prove

The confirmatory study, NCT04849741, enrolled 54 participants aged 1.5 to 53 years at 13 sites in eight countries, randomized 2:1 to drug or control for a 60-week double-blind period. Two dose cohorts ran, 25 mg and 50 mg, with 50 mg the confirmatory cohort, dosed every 12 weeks.

The headline result is a walking-speed statistic. In patients 5 and older with measurable walking difficulty at baseline, treated patients showed a 33.3% least-squares-mean advantage on the 10-Meter Walk Test at week 61 versus control, with p = 0.041. The p-value is real but modest, the kind that clears a bar rather than clears it comfortably. Children aged 2 to 4, where walking speed is not a reliable measure, improved on the Gross Motor Function Measure-88 while the control group declined.

Patient- and clinician-reported outcomes consistently favored the drug, and serious treatment-emergent adverse events occurred less often in the treated group than in control.

Today's approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no treatment options.— Brett P. Monia, Ph.D., Chief Executive Officer, Ionis

For infants under 2, the evidence is thinner. Direct clinical data were limited by rarity and the absence of a concurrent control group, so the FDA leaned on pharmacokinetic modeling showing expected drug levels similar to older children, plus safety data from four treated infants. The label covers them on that basis.

The limits the approval does not remove

The drug requires a lumbar puncture every three months, delivered by trained staff in a clinical setting. That is a hard logistics cost for a pediatric population. The most common adverse events were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Aseptic meningitis has been reported, and patients are told to watch for meningitis symptoms. None of this is disqualifying. All of it raises the per-patient cost of care, and for a disease affecting a few hundred people worldwide, per-patient cost is the entire economics of the program.

Ionis's first solo launch

It built its reputation through partnership. Its best-known drug, SPINRAZA (nusinersen), the first approved treatment for spinal muscular atrophy, is commercialized with Biogen. QALSODY and WAINUA followed the same playbook. Zanvastro is different: the company is launching it alone, its first independent launch from the neurology pipeline and its second independent launch this year.

That makes the approval a business test as much as a clinical one. The company has to build its own sales and patient-support infrastructure, run its own reimbursement work, and hold the product's full cost structure. It has set up a support program, Ionis Every Step, covering patient education, insurance-approval assistance, and affordability services.

Ultra-rare approvals are arriving in a cluster. As we wrote in September, the FDA approved Mimrylo (rusfertide), the first drug that ends phlebotomy for polycythemia vera. As we wrote in August, the agency cleared Jazz's Ziihera, a bispecific antibody, for first-line gastroesophageal adenocarcinoma.

The cluster matters for a specific reason. These are not blockbusters, and they never will be. They are first-in-class medicines for populations too small to attract classic development economics, unlocked by regulatory incentives and platform technologies that lower the cost of a new program. The question each one raises is the same: whether the sponsor can convert a scientific first into a durable commercial business.

Does an ultra-rare approval make Ionis a commercial company?

Development scenarios

Sources